Regeneron

News

Sanofi gets opt-in rights to two Regeneron cancer drugs

Sanofi and Regeneron have restructured and extended their immune-oncology discovery and development agreement, giving the French drugmaker rights to opt-in to development and marketing of t

News

Praluent not worth the price, finds study

Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed.

News

Amgen cuts US price of cholesterol drug by 60%

Amgen is cutting the US price of its cholesterol drug Repatha by 60%, following a similar decision by rivals Sanofi and Regeneron earlier this year.

News

FDA approves Sanofi/Regeneron's Dupixent in asthma

The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the companies attempt to build a blockbuster franchise around the drug.

News

Sanofi/Regeneron's Dupixent could be first biologic approved...

Trials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic rhinosinusitis with nasal polyps, teeing up a potential n

News